Erika L. Manyak

发表

First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections

A. Dane, D. Melnick, Vipul K. Gupta, 2021, Antimicrobial agents and chemotherapy.

Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model.

D. Ehmann, V. Galullo, Pratik Bhagunde, 2015, Journal of medicinal chemistry.

Safety, Pharmacokinetics, and Food Effect of Tebipenem Pivoxil Hydrobromide after Single and Multiple Ascending Oral Doses in Healthy Adult Subjects

P. Eckburg, A. Dane, D. Melnick, 2019, Antimicrobial Agents and Chemotherapy.

Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies

Hua Yang, S. Agresta, K. Le, 2015 .

Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Tebipenem Pivoxil Hydrobromide on QT/QTc Intervals in Healthy Subjects

P. Eckburg, D. Melnick, Vipul K. Gupta, 2021, Antimicrobial agents and chemotherapy.

Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial

Hua Yang, E. Attar, S. Agresta, 2015 .

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors

P. Wen, I. Mellinghoff, Hua Yang, 2019, Investigational New Drugs.

SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3.

A. Ferguson, Kerry E. Murphy-Benenato, Ning Gao, 2015, ACS medicinal chemistry letters.

A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.

T. Yap, G. Falchook, S. Parasuraman, 2021 .

866 RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in preclinical models and patient tumors

T. Yap, R. Abo, G. Falchook, 2021, Journal for ImmunoTherapy of Cancer.